Background -Reversibility after administration of an inhaled bronchodilator is not always demonstrable in patients with asthma. Bronchodilator aerosol-induced bronchoconstriction has also been reported to occur in some patients. Methods -Fifteen selected patients showing <10% improvement in forced expiratory volume in one second (FEV,) when tested with four doses of salbutamol (0.1 mg/dose) orterbutaline (0.25 mg/dose) from a pressurised metered dose inhaler (MDI) participated in two randomised, double blind studies. They received 2-0 mg terbutaline (4 x 2 doses of 0 25 mg) or a corresponding placebo from an MDI connected to a 750 ml spacer, and 10 mg (2xO*5mg) terbutaline or placebo from a multidose dry powder inhaler free of additives (Turbohaler). Results -Inhalation of placebo MDI resulted in a mean (SD) decrease in FEV, of 20 5 (14.1)% (range -42-9% to + 2-6%). In 14 patients inhalation of2-0 mg terbutaline MDI with spacer resulted in <10% improvement (mean increase 3-1 (6.0)%). 
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Discussion
The patients included in this study represented a subgroup of asthmatics who did not have a 10% improvement in FEV, after a standard reversibility test. They were all non-smokers and most were using inhaled corticosteroids. Apart from the difference in reversibility, the patients included did not differ clinically in any other respect from the rest of the original patient population.
In recent years attention has been drawn to bronchoconstrictive properties of additives in MDIs. Acute asthmatic attacks have been reported after use of 02 agonist aerosols.1A12-15
Between 1984 and 1988 109 cases of P agonistinduced acute bronchospasm were reported to the US Food and Drug Administration.' Acute attacks have also been reported after the use of adrenaline, isoetharine, isoprenaline, orciprenaline, salbutamol, and salmeterol inhalers.
Both chlorofluorocarbons and lubricants may be bronchoconstrictive.56 Ahmad studied 10 asthma patients who used placebo inhalers containing chlorofluorocarbon 12 or a mixture of chlorofluorocarbons 11 and 12. Both aerosols caused an immediate fall in FEV, with a mean decrease of 28% 21 minutes after inhalation.5 In another study 79 consecutively admitted asthmatic patients inhaled cumulative doses (2, 4, 8, and 16 doses) of a placebo MDI.6 A dose-response relation was found between the number of doses and the fall in FEV,.
After inhalation of up to 16 doses more than half the patients had a decrease in FEVy of >10%, and a quarter a reduction of >20%.6 In clinical practice the possible MDI additive-induced reduction in bronchodilatation has been regarded as a minor problem. 
